A Precision Ultrasound-Localized Sonoporation-Equipment (PULSE) Enabling Intratumoral Delivery for Cancer Immunotherapy

Cancer immunotherapy offers a promising long-term treatment for solid tumors by activating the immune system, but side effects and systemic toxicity limit its broad clinical translation. While intratumoral delivery addresses these limitations, elevated stiffness within solid tumors continues to hinder both intracellular and extracellular delivery. Here, a novel therapeutic platform, the Precision Ultrasound-Localized Sonoporation-Equipment (PULSE), is presented to enable spatiotemporally controlled, ultrasound-mediated gene and drug delivery for intratumoral immunotherapy. The PULSE incorporates forward and sideward-looking miniaturized ultrasound transducers, integrated into either a 7-French catheter (cPULSE) or a 16-gauge needle (nPULSE), to minimally invasively sonicate a centimeter-sized tumor. Following the design, prototyping, and characterization of PULSE, its dual capability for intracellular and extracellular delivery is demonstrated through comprehensive in vitro cell-based sonoporation tests and phantom-based drug penetration tests. Luciferase assays (activity: ~104 RLU/g level) in the cell studies confirm significantly enhanced gene transfection with cPULSE, while increased dye diffusion (width: ~1 cm level) in the phantom tests validates improved perfusion with nPULSE. The reported PULSE shows promise for spatiotemporally precise, controlled, and localized therapeutic delivery in early-stage tumors for intratumoral immunotherapy.